QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,754 signal articles · 476 in last 24h · 105,717 total before filter · latest 59m ago
476last 24h
2432last 7d
475● bullish (7d)
253● bearish (7d)
200publishers
AllMacro163Earnings1500M&A145Regulatory14Product8Analyst23
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
SpaceX's first earnings are coming: What investors need to watch
Yahoo Finance Video6d agoneutralVIDEO
SpaceX's first earnings are coming: What investors need to watch

Yahoo Finance Executive Editor Brian Sozzi and his panel break down the day's "Stock of the Day," SpaceX (SPCX), ahead of the company's first earnings report next week. Sozzi is joined by LPL Financial chief technical strategist Adam Turnquist, 42 Macro founder and CEO Darius Dale, and Senior Business reporter Ines Ferre.

Ares Management Q2 Earnings Call Highlights
MarketBeat6d agoneutral
Ares Management Q2 Earnings Call Highlights

Ares Management (NYSE:ARES) reported second-quarter results marked by record fundraising, higher fee-paying assets under management and double-digit growth in fee-related earnings and realized income, as the alternative investment manager expanded activity across credit, real assets, secondaries and

AbbVie Q2 Earnings Call Highlights
MarketBeat6d agoneutral
AbbVie Q2 Earnings Call Highlights

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p

Alliant Energy Q2 Earnings Call Highlights
MarketBeat6d agoneutral
Alliant Energy Q2 Earnings Call Highlights

Alliant Energy (NASDAQ:LNT) said it delivered second-quarter 2026 GAAP earnings of $0.65 per share and reaffirmed its full-year earnings guidance, with management saying results are trending in the upper half of the company’s range despite milder weather during the first half of the year. President

Where Apple is diverging from rest of Mag 7 earnings
Yahoo Finance Video6d agoneutralVIDEO
Where Apple is diverging from rest of Mag 7 earnings

Apple (AAPL) stock continues to drop on Friday while shares of Amazon (AMZN) surge since the two tech giants posted earnings results yesterday. Morning Brief Host Julie Hyman is joined by Yahoo Finance Breaking News Reporter Jake Conley and Trustless Media Founder Zack Guzman take a closer look at the key figures that Apple reported in its earnings release.

What Meta Now Has to Prove Following Its Earnings Release
24/7 Wall St.6d agoneutral
What Meta Now Has to Prove Following Its Earnings Release

At $585.61, Meta Platforms (NASDAQ:META) sits at a crossroads. The stock just snapped a six-quarter EPS beat streak and reset investor expectations around AI spending, making conviction in either direction premature at this price. Meta owns the largest social advertising network on the planet, monetizing 3.60 billion daily active users across Facebook, Instagram, WhatsApp, and ... What Meta Now Has to Prove Following Its Earnings Release

AI Traction Fuels Snowflake’s (SNOW) Guidance Boost
Insider Monkey6d agoneutral
AI Traction Fuels Snowflake’s (SNOW) Guidance Boost

Spyglass Capital Management LLC, an investment management firm, released its second-quarter investor letter for “Spyglass Growth Strategy”. A copy of the letter can be downloaded here. Spyglass Growth Strategy appreciated 24.63% in the second quarter, significantly outperforming the Bloomberg Midcap Growth Index’s 14.05% increase, the Bloomberg 2500 Growth Index’s 19.01% gain, and the Bloomberg 500 […]

Moderna Q2 Earnings Call Highlights
MarketBeat6d agoneutral
Moderna Q2 Earnings Call Highlights

Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha